Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Levosimendan in heart failure].

Laura Scelsi1, Carlo Campana, Stefano Ghio

  • 1Unità Cardiomiopatie, Scompenso cardiaco e Trapianto di Cuore, Divisione di Cardiologia, IRCCS Policlinico San Matteo, Pavia. emilio.corbellini@tin.it

Recenti Progressi in Medicina
|August 12, 2004
PubMed
Summary

Traditional inotropic agents for heart failure show increased mortality and limited benefits. Calcium-sensitizers like levosimendan offer a safer, more effective alternative, improving patient outcomes and ejection fraction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Giornale Italiano di Cardiologia: impact factor and impact to readers].

Giornale italiano di cardiologia (2006)·2026
Same author

[Presentation].

Giornale italiano di cardiologia (2006)·2026
Same author

[Giornale Italiano di Cardiologia and artificial intelligence].

Giornale italiano di cardiologia (2006)·2026
Same author

[The non-ST-elevation myocardial infarction network in Italy: still an unmet need].

Giornale italiano di cardiologia (2006)·2026
Same author

Giornale italiano di cardiologia (2006)·2026
Same author

[Presentation].

Giornale italiano di cardiologia (2006)·2026

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Traditional inotropic agents for heart failure are associated with increased mortality and significant side effects, limiting their clinical utility.
  • A new class of drugs, calcium-sensitizers, has been developed to improve heart failure treatment.
  • Levosimendan has demonstrated safety and efficacy in prior trials for various heart failure etiologies.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of levosimendan in patients with decompensated heart failure.
  • To assess the impact of levosimendan on clinical status and left ventricular ejection fraction.

Main Methods:

  • A study involving 26 patients with decompensated heart failure of diverse origins.
  • Treatment administered as a continuous 24-hour infusion of levosimendan.

Related Experiment Videos

Main Results:

  • Levosimendan administration led to improvements in the overall clinical status of patients.
  • A significant enhancement in left ventricular ejection fraction was observed post-treatment.
  • The study supports the positive impact of levosimendan in managing acute heart failure.

Conclusions:

  • Levosimendan represents a promising therapeutic option for decompensated heart failure.
  • The drug effectively improves cardiac function and clinical condition in heart failure patients.
  • Further research should explore long-term outcomes and broader applications of levosimendan.